Compared to Estimates, Encompass Health (EHC) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Encompass Health (EHC) reported revenue of $1.6 billion, up 9.6% over the same period last year. EPS came in at $1.55, compared to $1.40 in the year-ago quarter.

The reported revenue represents a surprise of +1.52% over the Zacks Consensus Estimate of $1.57 billion. With the consensus EPS estimate being $1.48, the EPS surprise was +4.73%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Encompass Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net patient revenue per discharge: $22,521.00 compared to the $22,065.23 average estimate based on two analysts.
• Discharges: 68,895 versus 69,042 estimated by two analysts on average.
• Net Operating Revenues- Inpatient: $1.55 billion compared to the $1.52 billion average estimate based on two analysts. The reported number represents a change of +9.8% year over year.
• Net Operating Revenues- Other: $45.8 million versus $47.42 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.1% change.

View all Key Company Metrics for Encompass Health here>>>

Shares of Encompass Health have returned -0.2% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research